Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ACTILYSE 2 mg is substantial. |
Clinical Added Value
| minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE. |
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
BVzm70SGueymBD9g
Listen
